CLBIO: Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales

About this update from Corline Biomedical Ab

Net sales declined year-over-year, but cost reductions improved quarterly results. Growth hinges on Kardium's US launch, with strong clinical data and new funding supporting expansion. The company is diversifying its customer base to reduce risk and drive future revenue.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Corline Biomedical Ab